Vir doses first patient in Phase 1 trial of EGFR-TCE VIR-5525; triggers $75M milestone payment to Sanofi

Vir Biotechnology, Inc.

First patient dosed in Phase 1 trial of VIR-5525, a dual-masked T-cell engager targeting EGFR, in solid tumors (NSCLC, CRC, HNSCC, cSCC).
Dosing triggers a $75M milestone payment to Sanofi under the 2024 license agreement, recognized as R&D expense in Q3 2025.
$75M milestone was held as restricted cash and excluded from the $1.02B cash reported as of March 31, 2025.
Dose escalation continues for TCEs VIR-5818 (HER2) and VIR-5500 (PSMA) in heavily pretreated patients, showing early response signals.
VIR-5525 is Vir's third dual-masked TCE in clinical trials; preclinical candidates integrating PRO-XTEN and AI discovery are advancing.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.